Research map: Stuck in traffic: CART cells targeting the tumor microenvironment in hematological malignancies, current advances and future perspectives

Back to the article

Papers in this map

  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma · Sattva Swarup Neelapu · 2017 · 6103 citations · Cited by this paper
  2. Evolutionary considerations for risk stratification in TP53-variant myeloproliferative neoplasms · 2026 · Related
  3. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia · Shannon L. Maude · 2018 · 5822 citations · Cited by this paper
  4. Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry · 2026 · Related
  5. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia · Jae H. Park · 2018 · 2735 citations · Cited by this paper
  6. Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance · 2026 · Related
  7. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas · Stephen J. Schuster · 2017 · 1891 citations · Cited by this paper
  8. Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis · 2026 · Related
  9. The role of interleukin-2 during homeostasis and activation of the immune system · Onur Boyman · 2012 · 1711 citations · Cited by this paper
  10. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia · 2026 · Related
  11. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma · Frederick Lundry Locke · 2021 · 1610 citations · Cited by this paper
  12. IKZF1N159S is associated with adverse outcomes in patients with myelodysplastic neoplasms · 2026 · Related
  13. Long-term outcomes following CAR T cell therapy: what we know so far · Kathryn M. Cappell · 2023 · 1414 citations · Cited by this paper
  14. Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma · 2026 · Related
  15. Tumor Antigen Escape from CAR T-cell Therapy · Robbie G. Majzner · 2018 · 1213 citations · Cited by this paper
  16. Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry · 2026 · Related
  17. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults · Rebecca Gardner · 2017 · 1156 citations · Cited by this paper
  18. Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms · 2026 · Related
  19. Mechanisms of resistance to CAR T cell therapy · Nirali N. Shah · 2019 · 989 citations · Cited by this paper
  20. Unpacking the epigenetic landscape of acute lymphoblastic leukemia: resolving cellular heterogeneity and nutritional complexities · 2026 · Related
  21. Phagocytosis checkpoints as new targets for cancer immunotherapy · Mingye Feng · 2019 · 953 citations · Cited by this paper
  22. CSF-1 Receptor Signaling in Myeloid Cells · E. Richard Stanley · 2014 · 843 citations · Cited by this paper
  23. The CD47-SIRPα Immune Checkpoint · Meike E. W. Logtenberg · 2020 · 776 citations · Cited by this paper
  24. T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma · Syed Abbas Ali · 2016 · 773 citations · Cited by this paper
  25. The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment · Lea Monteran · 2019 · 698 citations · Cited by this paper
  26. Colony-stimulating factor-1 in immunity and inflammation · Violeta Chiţu · 2005 · 638 citations · Cited by this paper
  27. Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy · Vita Golubovskaya · 2016 · 606 citations · Cited by this paper
  28. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia · Elena J. Orlando · 2018 · 590 citations · Cited by this paper
  29. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells · Partow Kebriaei · 2016 · 512 citations · Cited by this paper
  30. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia · Eric Tran · 2013 · 470 citations · Cited by this paper
  31. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer · Kipp Weiskopf · 2016 · 446 citations · Cited by this paper
  32. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma · Mehmet Samur · 2021 · 426 citations · Cited by this paper
  33. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model · Eloah Rabello Suarez · 2016 · 339 citations · Cited by this paper
  34. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties · Kevin Dooley · 2021 · 320 citations · Cited by this paper
  35. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma · Michael David Jain · 2021 · 307 citations · Cited by this paper
  36. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma · Nicholas J. Haradhvala · 2022 · 269 citations · Cited by this paper
  37. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma · Eugenia Zah · 2020 · 233 citations · Cited by this paper
  38. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity · Morgane Boulch · 2021 · 221 citations · Cited by this paper
  39. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma · Nathalie Scholler · 2022 · 210 citations · Cited by this paper

Source: OpenAlex (CC0)